OmniAb (OABI) Net Cash Flow Growth (3y) (2024 - 2026)

OmniAb (OABI) Net Cash Flow Growth (3y) (2024 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) NCF Growth (3y) (Qtr)
1 Oculis Holding AG 66,440.76 Bn 66,440.47 Bn - -50.33%
2 Nanobiotix 1,909.20 Bn 1,909.14 Bn - -
3 Akari Therapeutics 1,009.43 Bn 1,009.43 Bn - -
4 BeOne Medicines 468.28 Bn 463.49 Bn 1.35 Bn 38.47%
5 Vertex Pharmaceuticals 122.49 Bn 115.24 Bn 2.59 Bn 33.37%
6 Regeneron Pharmaceuticals 70.26 Bn 61.51 Bn 3.31 Bn -29.82%
7 Belite Bio 62.88 Bn 62.88 Bn - -
8 Argenx Se 55.67 Bn 50.48 Bn 1.41 Bn -
9 Alnylam Pharmaceuticals 37.37 Bn 34.36 Bn 959.66 Mn 32.17%
10 OmniAb 262.99 Mn 213.92 Mn 14.41 Mn 32.66%

Historic Data

Download Data
DateValue
Mar 31, 2026 32.66%
Dec 31, 2025 -27.83%
Dec 31, 2024 44.22%
Sep 30, 2024 -69.89%